Literature DB >> 27528361

Exploiting Microglial Functions for the Treatment of Glioblastoma.

Cinzia Dello Russo1, Lucia Lisi, Lucio Tentori, Pierluigi Navarra, Grazia Graziani, Colin K Combs.   

Abstract

BACKGROUND: Glioblastoma multiforme (GBM) is the most common brain tumor in adults and is associated with a very low survival rate. The heterogeneity of the tumor microenvironment, its resistance to drug and radiation therapy, and its robust invasiveness all contribute to the poor outcome. Large numbers of glioma associated microglia and macrophages (GAMs) can accumulate within the tumor where they appear to have an important role in prognosis.
METHODS: An extensive revision of current available literature on this topic has been carried out, using the PubMed database. Articles exploring the contribution of GAMs to GBM biology as well as evidence that GAMs can be pharmacologically modulated to inhibit tumor growth are critically discussed in this review article.
RESULTS: GAMs constitute the largest portion of tumor infiltrating cells contributing up to 30% of the entire glioma mass. Upon interaction with neoplastic cells, GAMs acquire a unique phenotype of activation including both M1 and M2 specific markers. Different profiles of activation usually co-exist in the same tumor that is dependent upon GAM location or stage of disease. In addition to regulating immune responses which may control or favor astrocyte malignant transformation, GAMs are directly involved in the degradation of the extracellular matrix (ECM), a crucial mechanism that allows the expansion of tumors and parenchyma invasion. Several pharmacological strategies have been developed which interfere with GAM recruitment at the tumor site, cell polarization and immune function, and ECM remodeling by GAM-secreted factors. The most promising therapeutic approaches appear to target both GBM cells and GAM biological properties.
CONCLUSION: GAMs significantly contribute to GBM biology (favoring tumor growth and invasiveness). Data reviewed in the present article suggest that these cells represent a valuable alternative/ additional target for the development of more effective treatments for GBM. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  ARG-1; Glioblastoma; M1; M2; NOS2; macrophages; metalloproteases; microglia

Mesh:

Substances:

Year:  2017        PMID: 27528361     DOI: 10.2174/1568009616666160813191240

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  23 in total

1.  An orthotopic glioblastoma animal model suitable for high-throughput screenings.

Authors:  Linda Pudelko; Steven Edwards; Mirela Balan; Daniel Nyqvist; Jonathan Al-Saadi; Johannes Dittmer; Ingrid Almlöf; Thomas Helleday; Lars Bräutigam
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

2.  Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Claudia Mattei; Flora Vitale; Francesco Marampon; Alessandro Colapietro; Giulia Rossi; Luca Ventura; Antonella Vetuschi; Ernesto Di Cesare; Judith A Fox; Claudio Festuccia
Journal:  Oncotarget       Date:  2017-05-02

Review 3.  Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors.

Authors:  Giuseppina D'Alessandro; Cristina Limatola; Myriam Catalano
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

4.  Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2.

Authors:  Xian-Qin Luo; Ao Li; Xue Yang; Xiao Xiao; Rong Hu; Tian-Wen Wang; Xiao-Yun Dou; Da-Jian Yang; Zhi Dong
Journal:  Chin Med       Date:  2018-03-20       Impact factor: 5.455

5.  Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling.

Authors:  Maciej Pudełek; Kamila Król; Jessica Catapano; Tomasz Wróbel; Jarosław Czyż; Damian Ryszawy
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

6.  CXCR4-STAT3 Axis Plays a Role in Tumor Cell Infiltration in an Orthotopic Mouse Glioblastoma Model.

Authors:  Ji-Hun Han; Jeong Seon Yoon; Da-Young Chang; Kyung Gi Cho; Jaejoon Lim; Sung-Soo Kim; Haeyoung Suh-Kim
Journal:  Mol Cells       Date:  2020-06-30       Impact factor: 5.034

7.  Identification of Key Differentially Expressed Transcription Factors in Glioblastoma.

Authors:  Gang Qin; Beiquan Hu; Xianfeng Li; Rongjie Li; Youshi Meng; Yimei Wang; Donghua Zou; Feng Wei
Journal:  J Oncol       Date:  2020-06-15       Impact factor: 4.375

8.  Microglia induces Gas1 expression in human brain tumor-initiating cells to reduce tumorigenecity.

Authors:  Susobhan Sarkar; Candice C Poon; Reza Mirzaei; Khalil S Rawji; Walter Hader; Pinaki Bose; John Kelly; Jeffrey F Dunn; V Wee Yong
Journal:  Sci Rep       Date:  2018-10-16       Impact factor: 4.379

Review 9.  Microglia at center stage: a comprehensive review about the versatile and unique residential macrophages of the central nervous system.

Authors:  Nils Lannes; Elisabeth Eppler; Samar Etemad; Peter Yotovski; Luis Filgueira
Journal:  Oncotarget       Date:  2017-12-11

Review 10.  The human microglial HMC3 cell line: where do we stand? A systematic literature review.

Authors:  Cinzia Dello Russo; Natalia Cappoli; Isabella Coletta; Daniele Mezzogori; Fabiola Paciello; Giacomo Pozzoli; Pierluigi Navarra; Alessandra Battaglia
Journal:  J Neuroinflammation       Date:  2018-09-10       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.